U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Imipenem-cilastatin-relebactam Injection
  1. Development Resources

Imipenem-cilastatin-relebactam Injection

Exceptions or additions to the recognized standards

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion a
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Acinetobacter calcoaceticus-baumannii complex

≤2/4

4/4

≥8/4

-

-

-

Haemophilus influenzae

≤4/4

-

-

-

-

-

S = Susceptible; I = Intermediate; R = Resistant

a For disk diffusion, use paper disks impregnated with imipenem/relebactam at a concentration of 10/25 mcg.
For Enterobacteriaceae, clinical efficacy was shown for Klebsiella aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Klebsiella oxytoca.
For Anaerobes, clinical efficacy was shown for Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Fusobacterium nucleatum, Parabacteroides distasonis. STIC are based on the agar dilution method.

Back to Top